08:43 AM EST, 01/14/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Tuesday that it has obtained exclusive commercial rights in the US and Canada to Hikma Pharmaceuticals' Kloxxado Nasal Spray, an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose.

Financial terms were not disclosed.

Under the terms of the six-year agreement, Emergent said Hikma will continue to manufacture Kloxxado Nasal Spray 8 mg, which will become part of Emergent's NARCANDirect online distribution network for direct purchasers, such as emergency medical services.

Emergent's shares were up about 3% in recent premarket activity.